MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtronic Wins Breakthrough Device Designation for TYRX

IMG_Sep222020at32432PM[1].jpg Sundry
The Dublin-based company said TYRX is intended to securely hold a percutaneous driveline in patients.

Medtronic is keeping the product fires warm with a new breakthrough device designation aimed at enhancing ventricular assist devices (VAD). The Dublin-based company said on Tuesday FDA had granted it the destination for the TYRX Absorbable Antibacterial Driveline Wrap.

TYRX is intended to securely hold a percutaneous driveline in patients. A vital component of VAD systems, the driveline connects the implanted heart pump to an external controller that is powered by an AC or DC adapter, or external batteries. Because the driveline extends outside the body, it is susceptible to infection. 

To help reduce driveline complications, the TYRX can be used It is fully absorbed by the body approximately nine weeks after implantation,  and stabilizes a cardiac implantable electronic device such as a pacemaker or implantable defibrillator, or an implanted neurostimulator.

Medtronic’s most famous device in the VAD market is its HVAD system. The company inherited the technology when it acquired HeartWare in 2016 for $1.1 billion. A little more than two years ago, Medtronic gained a nod for a less invasive implantable approach of the HVAD system.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.